Enhabit, Inc. (NYSE:EHAB – Get Free Report) Director Jeffrey Bolton purchased 4,000 shares of the company’s stock in a transaction that occurred on Thursday, December 12th. The shares were purchased at an average price of $8.69 per share, for a total transaction of $34,760.00. Following the purchase, the director now directly owns 98,144 shares in the company, valued at $852,871.36. The trade was a 4.25 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Enhabit Stock Performance
Shares of EHAB stock opened at $8.52 on Friday. The business’s 50 day moving average is $7.56 and its two-hundred day moving average is $8.31. Enhabit, Inc. has a twelve month low of $6.85 and a twelve month high of $11.74. The company has a market capitalization of $428.42 million, a P/E ratio of -3.67 and a beta of 1.89. The company has a current ratio of 1.46, a quick ratio of 1.46 and a debt-to-equity ratio of 0.85.
Enhabit (NYSE:EHAB – Get Free Report) last announced its earnings results on Wednesday, November 6th. The company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.01). Enhabit had a negative net margin of 11.24% and a positive return on equity of 1.67%. The company had revenue of $253.60 million during the quarter, compared to analysts’ expectations of $261.69 million. During the same quarter last year, the business posted $0.03 earnings per share. Equities analysts forecast that Enhabit, Inc. will post 0.22 EPS for the current year.
Institutional Inflows and Outflows
Wall Street Analyst Weigh In
EHAB has been the topic of a number of research reports. Leerink Partners restated a “market perform” rating and set a $8.00 price target (down previously from $8.50) on shares of Enhabit in a research note on Tuesday, November 19th. Jefferies Financial Group upgraded Enhabit from a “hold” rating to a “buy” rating and raised their price target for the stock from $8.25 to $9.50 in a research note on Monday, December 9th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $8.75.
Get Our Latest Research Report on EHAB
Enhabit Company Profile
Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.
See Also
- Five stocks we like better than Enhabit
- Bank Stocks – Best Bank Stocks to Invest In
- Why Hershey Stock Has More Room to Run Despite Takeover Rejection
- Airline Stocks – Top Airline Stocks to Buy Now
- Texas Instruments: The Old-School Tech Titan Still Delivering
- How to Invest in Small Cap StocksĀ
- GRAIL: Biotech Stock Targeting $100B Cancer Market
Receive News & Ratings for Enhabit Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enhabit and related companies with MarketBeat.com's FREE daily email newsletter.